Imeri, Faik; Schwalm, Stephanie; Lyck, Ruth; Zivkovic, Aleksandra; Stark, Holger; Engelhardt, Britta; Pfeilschifter, Josef; Huwiler, Andrea (2016). Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments. Neuropharmacology, 105, pp. 341-350. Elsevier 10.1016/j.neuropharm.2016.01.031
Text
Huwiler_Spingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis Resistance to FTY720 but not ST-968 treatments.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (2MB) |
The immunomodulatory drug FTY720 is presently approved for the treatment of relapsing-remitting multiple sclerosis. It is a prodrug that requires activation by sphingosine kinase 2 (SK-2) to induce T cell homing to secondary lymphoid tissue. In this study, we have investigated the role of SK-2 in experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. We show that SK-2 deficiency reduced clinical symptoms of EAE. Furthermore, in SK-2-deficient mice, the protective effect of FTY720 on EAE was abolished, while the non-prodrug FTY720-derivative ST-968 was still fully active. Protection was paralleled by reduced numbers of T-lymphocytes in blood and a reduced blood-brain-barrier leakage. This correlated with reduced mRNA expression of ICAM-1, VCAM-1, but enhanced expression of PECAM-1. A similar regulation of permeability and of PECAM-1 was seen in primary cultures of isolated mouse brain vascular endothelial cells and in a human immortalized cell line upon SK-2 knockdown. In summary, these data demonstrated that deletion of SK-2 exerts a protective effect on the pathogenesis of EAE in C57BL/6 mice and that SK-2 is essential for the protective effect of FTY720 but not of ST-968. Thus, ST-968 is a promising novel immunomodulatory compound that may be a valuable alternative to FTY720 under conditions where SK-2 activity is limited.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology 04 Faculty of Medicine > Pre-clinic Human Medicine > Theodor Kocher Institute |
Graduate School: |
Graduate School for Cellular and Biomedical Sciences (GCB) |
UniBE Contributor: |
Imeri, Faik, Schwalm, Stephanie, Lyck, Ruth, Engelhardt, Britta, Huwiler, Andrea |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0028-3908 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Debora Scherrer |
Date Deposited: |
14 Mar 2016 15:27 |
Last Modified: |
05 Dec 2022 14:53 |
Publisher DOI: |
10.1016/j.neuropharm.2016.01.031 |
PubMed ID: |
26808312 |
Uncontrolled Keywords: |
Blood-brain-barrier; Endothelial cells; Experimental autoimmune encephalomyelitis; FTY720; ST-968; Sphingosine kinase 2 |
BORIS DOI: |
10.7892/boris.79017 |
URI: |
https://boris.unibe.ch/id/eprint/79017 |